T20K Combo Shows Promise in MS Preclinical Studies

T20K Combo Shows Promise in MS Preclinical Studies

310501

T20K Combo Shows Promise in MS Preclinical Studies

New preclinical data continues to support the potential of Cyxone’s investigational plant-derived peptide T20K for the treatment of multiple sclerosis (MS). In a collaboration with its academic partner, the Medical University of Vienna, Cyxone has shown that a combination of T20K plus an activator of the kappa opioid receptor (kappa OR) has greater benefits than any treatment alone at preventing disease mechanisms in MS. “We are very pleased that our collaboration with researchers at the…

You must be logged in to read/download the full post.